Phase 4 N=68 Randomized Single-blind Treatment

Effects of N-acetylcysteine on Low T3 Syndrome

Acute Myocardial Infarction · Euthyroid Sick Syndrome · Ischemic Heart Disease

Bottom Line

View on ClinicalTrials.gov: NCT01501110 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2015

Primary outcome: Primary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: N-acetylcysteine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Federal University of Rio Grande do Sul
Primary completion: Jul 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum T3 Levels at 48 Hours	93.5; 96.5	—

Summary

The propose of this study is to determine whether N-acetylcysteine is effective in reversing the changes in thyroid hormones seen in critical illness, known as the low T3 syndrome.

Eligibility Criteria

Inclusion Criteria

diagnosis of acute myocardial infarction with less than 12 hours of evolution
reperfusion therapy (primary angioplasty)

Exclusion Criteria

Thyroid disease
Chronic renal disease with renal replacement therapy
hepatic insufficiency
immunosuppression

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01501110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.